NF-κB-inducing kinase (NIK) promotes hyperglycemia and glucose intolerance in obesity by augmenting glucagon action

Nature Medicine

Volumn 18, Issue 6, 2012, Pages 943-949

  Sheng, Liang ^a   Zhou, Yingjiang ^a   Chen, Zheng ^a   Ren, Decheng ^a   Cho, Kae Won ^a   Jiang, Lin ^a   Shen, Hong ^a   Sasaki, Yoshiteru ^b   Rui, Liangyou ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b RIKEN Center for Biosystems Dynamics Research   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ENZYME ACTIVATOR; GLUCAGON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN INDUCING KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME SPECIFICITY; GENE DELETION; GENE OVEREXPRESSION; GENETIC CODE; GLUCONEOGENESIS; GLUCOSE INTOLERANCE; HYPERGLYCEMIA; LIVER CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PRIORITY JOURNAL;

ANIMALS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; GLUCAGON; GLUCOSE; GLUCOSE INTOLERANCE; HYPERGLYCEMIA; LIVER; MALE; MICE; MICE, INBRED C57BL; MICROTUBULE-ASSOCIATED PROTEINS; OBESITY; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES;

MUS;

EID: 84862000588     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2756     Document Type: Article

References (37)

1. Hotamisligil, G.S. Inflammation and metabolic disorders. Nature 444, 860-867 (2006). (Pubitemid 46024993)
2. Shoelson, S.E. & Goldfine, A.B. Getting away from glucose: fanning the flames of obesity-induced inflammation. Nat. Med. 15, 373-374 (2009).
3. Arkan, M.C. et al. IKK-β links inflammation to obesity-induced insulin resistance. Nat. Med. 11, 191-198 (2005). (Pubitemid 40321355)
4. Cai, D. et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat. Med. 11, 183-190 (2005). (Pubitemid 40321354)
5. Yuan, M. et al. Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 293, 1673-1677 (2001). (Pubitemid 32807849)
6. Unger, R.H. & Cherrington, A.D. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J. Clin. Invest. 122, 4-12 (2012).
7. Jiang, G. & Zhang, B.B. Glucagon and regulation of glucose metabolism. Am. J. Physiol. Endocrinol. Metab. 284, E671-E678 (2003). (Pubitemid 36323859)
8. Denroche, H.C. et al. Leptin therapy reverses hyperglycemia in mice with streptozotocin-induced diabetes, independent of hepatic leptin signaling. Diabetes 60, 1414-1423 (2011).
9. Yu, X., Park, B.H., Wang, M.Y., Wang, Z.V. & Unger, R.H. Making insulin-deficient type 1 diabetic rodents thrive without insulin. Proc. Natl. Acad. Sci. USA 105, 14070-14075 (2008).
10. Lee, Y., Wang, M.Y., Du, X.Q., Charron, M.J. & Unger, R.H. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 60, 391-397 (2011).
11. Cummings, B.P. et al. Subcutaneous administration of leptin normalizes fasting plasma glucose in obese type 2 diabetic UCD-T2DM rats. Proc. Natl. Acad. Sci. USA 108, 14670-14675 (2011).
12. Maruyama, H., Hisatomi, A., Orci, L., Grodsky, G.M. & Unger, R.H. Insulin within islets is a physiologic glucagon release inhibitor. J. Clin. Invest. 74, 2296-2299 (1984). (Pubitemid 15197376)
13. Thu, Y.M. & Richmond, A. NF-κB inducing kinase: a key regulator in the immune system and in cancer. Cytokine Growth Factor Rev. 21, 213-226 (2010).
14. Sun, S.C. Non-canonical NF-κB signaling pathway. Cell Res. 21, 71-85 (2011).
15. Yin, L. et al. Defective lymphotoxin-β receptor-induced NF-κB transcriptional activity in NIK-deficient mice. Science 291, 2162-2165 (2001). (Pubitemid 32224449)
16. Murray, S.E. et al. NF-κB-inducing kinase plays an essential T cell-intrinsic role in graft-versus-host disease and lethal autoimmunity in mice. J. Clin. Invest. 121, 4775-4786 (2011).
17. Ling, L., Cao, Z. & Goeddel, D.V. NF-κB-inducing kinase activates IKK-α by phosphorylation of Ser-176. Proc. Natl. Acad. Sci. USA 95, 3792-3797 (1998). (Pubitemid 28173208)
18. Xiao, G., Fong, A. & Sun, S.C. Induction of p100 processing by NF-κB-inducing kinase involves docking IκB kinase α (IKKα) to p100 and IKKα-mediated phosphorylation. J. Biol. Chem. 279, 30099-30105 (2004). (Pubitemid 38937932)
19. Xiao, G., Harhaj, E.W. & Sun, S.C. NF-κB-inducing kinase regulates the processing of NF-κB2 p100. Mol. Cell 7, 401-409 (2001). (Pubitemid 32206507)
20. Malinin, N.L., Boldin, M.P., Kovalenko, A.V. & Wallach, D. MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature 385, 540-544 (1997). (Pubitemid 27074673)
21. Ninomiya-Tsuji, J. et al. The kinase TAK1 can activate the NIK-I κB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 398, 252-256 (1999).
22. Sasaki, Y. et al. NIK overexpression amplifies, whereas ablation of its TRAF3-binding domain replaces BAFF:BAFF-R-mediated survival signals in B cells. Proc. Natl. Acad. Sci. USA 105, 10883-10888 (2008).
23. Herzig, S. et al. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 413, 179-183 (2001). (Pubitemid 32867880)
24. Zhou, X.Y. et al. Insulin regulation of hepatic gluconeogenesis through phosphorylation of CREB-binding protein. Nat. Med. 10, 633-637 (2004). (Pubitemid 38796855)
25. Koo, S.H. et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437, 1109-1111 (2005).
26. He, L. et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 137, 635-646 (2009).
27. Yoon, J.C. et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413, 131-138 (2001). (Pubitemid 32867868)
28. Liao, G., Zhang, M., Harhaj, E.W. & Sun, S.C. Regulation of the NF-κB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J. Biol. Chem. 279, 26243-26250 (2004). (Pubitemid 38798772)
29. Vallabhapurapu, S. et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-κB signaling. Nat. Immunol. 9, 1364-1370 (2008).
30. Zarnegar, B.J. et al. Noncanonical NF-κB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat. Immunol. 9, 1371-1378 (2008).
31. Duan, C., Yang, H., White, M.F. & Rui, L. Disruption of the SH2-B gene causes age-dependent insulin resistance and glucose intolerance. Mol. Cell. Biol. 24, 7435-7443 (2004). (Pubitemid 39121472)
32. Aoki, K. et al. Dehydroepiandrosterone suppresses the elevated hepatic glucose-6-phosphatase and fructose-1,6-bisphosphatase activities in C57BL/Ksj-db/db mice: comparison with troglitazone. Diabetes 48, 1579-1585 (1999). (Pubitemid 29356866)
33. Ren, D. et al. Neuronal SH2B1 is essential for controlling energy and glucose homeostasis. J. Clin. Invest. 117, 397-406 (2007). (Pubitemid 46203968)
34. Zhou, Y., Jiang, L. & Rui, L. Identification of MUP1 as a regulator for glucose and lipid metabolism in mice. J. Biol. Chem. 284, 11152-11159 (2009).
35. Huang, W., Dedousis, N., Bhatt, B.A. & O'Doherty, R.M. Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in diet-induced obesity. J. Biol. Chem. 279, 21695-21700 (2004). (Pubitemid 38679354)
36. Cho, K.W., Zhou, Y., Sheng, L. & Rui, L. Lipocalin-13 regulates glucose metabolism by both insulin-dependent and insulin-independent mechanisms. Mol. Cell. Biol. 31, 450-457 (2011).
37. Sheng, L., Cho, K.W., Zhou, Y., Shen, H. & Rui, L. Lipocalin 13 protein protects against hepatic steatosis by both inhibiting lipogenesis and stimulating fatty acid β-oxidation. J. Biol. Chem. 286, 38128-38135 (2011).